Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Induction of Cross-reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine

Vivek Shinde, Rongman Cai, Joyce Plested, Iksung Cho, Jamie Fiske, Xuan Pham, Mingzhu Zhu, Shane Cloney-Clark, Nan Wang, Haixia Zhou, Bin Zhou, Nita Patel, Michael J Massare, Amy Fix, Michelle Spindler, David Nigel Thomas, Gale Smith, Louis Fries, Gregory M Glenn
doi: https://doi.org/10.1101/2020.05.11.20098574
Vivek Shinde
1Novavax, Inc., 22 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: vshinde@novavax.com
Rongman Cai
2Previously with Novavax, Inc., 20 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joyce Plested
1Novavax, Inc., 22 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iksung Cho
1Novavax, Inc., 22 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jamie Fiske
1Novavax, Inc., 22 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuan Pham
2Previously with Novavax, Inc., 20 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingzhu Zhu
1Novavax, Inc., 22 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shane Cloney-Clark
1Novavax, Inc., 22 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nan Wang
2Previously with Novavax, Inc., 20 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haixia Zhou
1Novavax, Inc., 22 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bin Zhou
1Novavax, Inc., 22 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nita Patel
1Novavax, Inc., 22 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J Massare
1Novavax, Inc., 22 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Fix
2Previously with Novavax, Inc., 20 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Spindler
2Previously with Novavax, Inc., 20 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Nigel Thomas
2Previously with Novavax, Inc., 20 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gale Smith
1Novavax, Inc., 22 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis Fries
1Novavax, Inc., 22 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory M Glenn
1Novavax, Inc., 22 Firstfield Road, Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gglenn@novavax.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Recurrent reports of suboptimal influenza vaccine effectiveness have renewed calls to develop improved, broadly cross-protective influenza vaccines. Here, we evaluated the safety and immunogenicity of a novel, saponin (Matrix-M)-adjuvanted, recombinant hemagglutinin (HA) quadrivalent nanoparticle influenza vaccine (qNIV).

Methods We conducted a randomized, observer-blind, comparator-controlled (trivalent high-dose inactivated influenza vaccine [IIV3-HD], or quadrivalent recombinant influenza vaccine [RIV4]), safety and immunogenicity trial of qNIV (in 5 different doses/formulations) in healthy adults aged ≥65 years. Vaccine immunogenicity was measured by hemagglutination-inhibition assays using reagents expressing wild-type HA sequences (wt-HAI) and cell-mediated immune (CMI) responses.

Results A total of 1375 participants were randomized, immunized, and followed for safety and immunogenicity. Matrix-M-adjuvanted qNIV induced superior wt-HAI antibody responses against 5 of 6 homologous or drifted strains evaluated compared to unadjuvanted qNIV. Adjuvanted qNIV induced post-vaccination wt-HAI antibody responses at Day 28 that were: statistically higher than IIV3-HD against a panel of homologous or drifted A/H3N2 strains; similar to IIV3-HD against homologous A/H1N1 and B (Victoria) strains; and similar to RIV4 against all homologous and drifted strains evaluated. The qNIV formulation with 75 μg Matrix-M adjuvant induced substantially higher post-vaccination geometric mean fold-increases of influenza HA-specific polyfunctional CD4+ T-cells compared to IIV3-HD or RIV4. Overall, similar frequencies of solicited and unsolicited adverse events (AEs) were reported in all treatment groups.

Conclusions qNIV with 75 μg Matrix-M adjuvant was well tolerated and induced robust antibody and cellular responses, notably against both homologous and drifted A/H3N2 viruses. Further investigation in a pivotal phase 3 trial is underway.

SHORT SUMMARY We compared multiple formulations of a recombinant Matrix-M-adjuvanted nanoparticle influenza vaccine to 2 licensed influenza vaccines in older adults. The nanoparticle vaccine was well tolerated, and induced hemagglutination-inhibition antibody and CD4+ T-cell responses to vaccine-homologous and drifted A/H3N2 influenza viruses.

Competing Interest Statement

Vivek Shinde, Joyce Plested, Iksung Cho, Jamie Fiske, Mingzhu Zhu, Shane Cloney-Clark, Haixia Zhou, Bin Zhou, Nita Patel, Michael J Massare, Gale Smith, Louis Fries, and Gregory M Glenn are current employees of Novavax, Inc. Amy Fix, David Nigel Thomas, Michelle Spindler, Rongman Cai, Nan Wang, and Xuan Pham are former employees of Novavax, Inc.

Clinical Trial

NCT03658629

Funding Statement

This work was supported by the sponsor, Novavax Inc. (Gaithersburg, MD, USA).

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets generated during and/or analyzed during the current study are not publicly available as analyses are ongoing and will be used for regulatory submissions for the vaccine described; but may become available in the future from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 18, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Induction of Cross-reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Induction of Cross-reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine
Vivek Shinde, Rongman Cai, Joyce Plested, Iksung Cho, Jamie Fiske, Xuan Pham, Mingzhu Zhu, Shane Cloney-Clark, Nan Wang, Haixia Zhou, Bin Zhou, Nita Patel, Michael J Massare, Amy Fix, Michelle Spindler, David Nigel Thomas, Gale Smith, Louis Fries, Gregory M Glenn
medRxiv 2020.05.11.20098574; doi: https://doi.org/10.1101/2020.05.11.20098574
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Induction of Cross-reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine
Vivek Shinde, Rongman Cai, Joyce Plested, Iksung Cho, Jamie Fiske, Xuan Pham, Mingzhu Zhu, Shane Cloney-Clark, Nan Wang, Haixia Zhou, Bin Zhou, Nita Patel, Michael J Massare, Amy Fix, Michelle Spindler, David Nigel Thomas, Gale Smith, Louis Fries, Gregory M Glenn
medRxiv 2020.05.11.20098574; doi: https://doi.org/10.1101/2020.05.11.20098574

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (144)
  • Anesthesia (47)
  • Cardiovascular Medicine (419)
  • Dentistry and Oral Medicine (72)
  • Dermatology (49)
  • Emergency Medicine (147)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (174)
  • Epidemiology (4906)
  • Forensic Medicine (3)
  • Gastroenterology (185)
  • Genetic and Genomic Medicine (689)
  • Geriatric Medicine (72)
  • Health Economics (193)
  • Health Informatics (636)
  • Health Policy (322)
  • Health Systems and Quality Improvement (209)
  • Hematology (86)
  • HIV/AIDS (157)
  • Infectious Diseases (except HIV/AIDS) (5408)
  • Intensive Care and Critical Care Medicine (333)
  • Medical Education (96)
  • Medical Ethics (24)
  • Nephrology (77)
  • Neurology (692)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (128)
  • Occupational and Environmental Health (211)
  • Oncology (447)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (91)
  • Pain Medicine (37)
  • Palliative Medicine (18)
  • Pathology (131)
  • Pediatrics (201)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (88)
  • Psychiatry and Clinical Psychology (787)
  • Public and Global Health (1832)
  • Radiology and Imaging (328)
  • Rehabilitation Medicine and Physical Therapy (142)
  • Respiratory Medicine (257)
  • Rheumatology (87)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (63)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (38)